Amneal Pharmaceuticals AMRX Income Statement (2017-2026)

NASDAQ AMRX
$21.47 +0.09 (+0.42%)
As of: Nov 16, 2026 · 9:43 AM EST
Reported Financials

Amneal Pharmaceuticals Quarterly Income Statement

Periods 38 quarters
Latest Sep 2026

Amneal Pharmaceuticals reported revenue of $862.68M and net income of $12.31M for the quarter ended Sep 2026, up 10.0% year over year. This income statement covers 38 quarters of results from Jun 2017 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
536.90M497.63M559.36M545.56M609.76M557.54M599.05M620.04M616.98M659.19M701.78M702.47M730.52M695.42M724.51M784.51M814.32M722.52M796.20M862.68M
Cost of RevenueCost of Rev
371.18M323.06M358.84M351.33M394.37M379.35M379.03M387.51M427.15M421.13M451.83M432.91M467.65M439.53M438.26M510.54M517.13M402.41M461.69M528.57M
Gross Profit
166.40M174.57M200.52M194.23M215.39M178.19M220.02M232.53M189.83M238.06M249.95M269.56M262.87M255.89M286.25M273.97M297.19M320.11M334.51M334.12M
Operating items
Research & DevelopmentR&D
51.87M52.80M50.75M50.24M41.91M38.69M37.80M41.38M46.09M39.30M36.05M61.10M54.27M40.04M47.96M63.35M34.82M38.38M39.02M68.37M
Selling, General & AdministrativeSG&A
97.22M98.67M98.81M100.07M102.16M102.10M105.57M113.01M109.00M112.60M116.46M118.69M128.69M118.29M124.27M137.82M146.46M138.86M148.72M139.65M
Restructuring CostsRestructuring
7.31M0.73M0.58M0.11M0.51M0.08M1.04M0.11M1.47M0.22M0.17M0.49M0.57M1.02M0.14M2.47M5.15M7.60M0.94M
Other Operating ExpensesOther Opex
-0.16M3.09M-249.17M2.45M-23.54M3.30M-1.21M3.43M8.28M-94.46M-0.70M1.18M-1.79M5.12M0.39M0.12M0.00M6.24M-6.80M-11.87M
Operating ExpensesOpex
156.41M152.19M149.55M150.89M144.17M141.30M143.45M155.42M155.20M153.36M152.74M179.96M183.45M158.90M173.25M201.31M183.75M182.40M195.34M208.96M
Operating IncomeOp. Inc
11.18M23.31M-198.62M44.35M36.03M34.45M80.08M75.65M14.19M-10.75M95.47M88.81M75.79M100.35M111.37M70.34M112.03M141.77M129.77M95.42M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
Other Non Operating IncomeOther Non Op Inc.
6.46M0.11M1.51M0.22M3.97M6.27M0.84M-1.11M-36.89M2.88M4.10M3.45M-5.49M4.77M9.86M-33.56M11.69M-10.57M-1.30M-8.45M
Non Operating IncomeNon Op. Inc.
-27.49M-33.23M-34.11M-42.17M-43.69M-43.88M-50.42M-52.69M-97.65M-64.78M-75.07M-73.39M-91.11M-62.86M-59.66M-75.57M-56.80M-61.60M-58.78M-80.36M
Net income details
EBIT
11.18M23.31M-198.62M44.35M36.03M34.45M80.08M75.65M14.19M-10.75M95.47M88.81M75.79M100.35M111.37M70.34M112.03M141.77M129.77M95.42M
EBT
-16.32M-9.92M-232.73M2.18M-7.66M-9.43M29.66M22.96M-83.46M-75.52M20.41M15.42M-15.32M37.49M51.71M-5.22M55.24M80.18M70.99M15.06M
Tax ProvisionsTaxes
4.10M-3.50M7.40M4.60M-1.80M0.70M-0.02M-2.10M9.88M6.16M3.62M3.67M5.42M12.87M16.10M-23.36M5.66M2.18M1.38M2.75M
Income After Tax
-20.42M-6.42M-240.13M-2.42M-5.86M-10.13M29.68M25.06M-93.34M-81.68M16.79M11.76M-20.74M24.62M35.61M18.13M49.57M78.00M69.61M12.31M
Income from Continuing OperationsIncome (Continuing)
-20.42M-6.42M-240.13M-2.42M-5.86M-10.13M29.68M25.06M-93.34M-81.68M16.79M11.76M-20.74M24.62M35.61M18.13M49.57M78.00M69.61M12.31M
Consolidated Net IncomeConsol Net Inc.
-20.46M-6.46M-240.08M-2.39M-5.86M-10.09M29.68M25.03M-93.34M-81.68M16.79M11.76M-20.74M24.62M35.61M18.13M49.57M78.00M69.61M12.31M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
-14.08M-4.74M-119.27M0.30M-1.53M-3.15M17.77M15.35M5.31M9.97M10.79M11.91M10.34M12.42M13.19M15.76M14.50M15.74M11.95M19.76M
Income towards Parent CompanyParent Net Inc
-21.80M-8.82M-242.13M-7.61M129.01M-6.94M11.92M9.68M-98.65M-91.64M5.99M-0.16M-31.08M12.20M22.42M2.37M35.08M62.26M57.66M-21.70M
Preferred Dividend PaymentsPref Dividends
0.44M
Net Income towards Common StockholdersNet Income
-6.38M-2.16M-120.81M-2.69M-4.33M-6.94M11.92M9.68M-98.65M-91.64M5.99M-0.16M-31.08M12.20M22.42M2.37M35.08M62.26M57.66M-21.70M
Additional items
EPS (Basic)
-0.04-0.01-0.80-0.02-0.03-0.050.080.06-0.56-0.300.020.00-0.100.040.070.010.110.200.18-0.06
EPS (Diluted)
-0.04-0.01-0.80-0.02-0.03-0.050.080.06-0.56-0.300.020.00-0.100.040.070.010.110.190.18-0.06
Shares Outstanding
148.92M149.89M150.99M151.39M150.94M152.11M153.74M154.22M176.14M307.28M309.12M309.65M308.98M311.05M313.74M314.17M313.37M316.02M319.20M335.73M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
151.82M149.89M150.99M151.39M150.94M152.11M154.89M159.69M176.14M307.28M318.96M309.65M308.98M323.96M322.36M324.75M324.81M328.93M328.10M335.73M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
301.53M302.89M303.31M303.54M303.62M305.44M306.31M306.46M306.46M308.65M309.54M309.84M309.97M313.42M314.08M314.36M314.63M319.02M319.35M348.41M
EBITDA
74.69M83.32M-136.73M76.56M99.19M94.66M139.66M142.72M75.79M51.59M158.49M157.80M148.74M169.02M183.66M122.86M164.98M188.85M181.63M152.86M
Tax Rate
211.01%17.73%23.77%34.33%31.14%10.25%2.71%1.94%18.27%

Amneal Pharmaceuticals Income Statement API

Pull Amneal Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AMRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY